Zhimeng Biopharma has completed the patients enrollment of its investigational drug, CB03-154, in the pivotal Phase 2/3 ALS clinical trial.
- Saturday, October 31, 2026, 2:12
- PR Newswire
- Add a comment
SHANGHAI, Oct. 31, 2026 /PRNewswire/ — Shanghai Zhimeng Biopharma, Inc. ( “Zhimeng Biopharma”) announced today that its independently developed next-generation potassium channel opener, CB03-154, intended for the treatment of amyotrophic lateral sclerosis (ALS), has successfully…
About the Author
admin has written 21995 stories on this site.